Ultimovacs Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenure7.6yrs
Board average tenureno data

Recent management updates

Recent updates

Companies Like Ultimovacs (OB:ULTI) Can Afford To Invest In Growth

Feb 21
Companies Like Ultimovacs (OB:ULTI) Can Afford To Invest In Growth

Ultimovacs (OB:ULTI) Is In A Strong Position To Grow Its Business

Oct 26
Ultimovacs (OB:ULTI) Is In A Strong Position To Grow Its Business

Companies Like Ultimovacs (OB:ULTI) Are In A Position To Invest In Growth

Oct 05
Companies Like Ultimovacs (OB:ULTI) Are In A Position To Invest In Growth

Ultimovacs (OB:ULTI) Is In A Good Position To Deliver On Growth Plans

May 19
Ultimovacs (OB:ULTI) Is In A Good Position To Deliver On Growth Plans

CEO

Ultimovacs has no CEO, or we have no data on them.


Leadership Team

NamePositionTenureCompensationOwnership
Hans Eid
Chief Financial Officer9.3yrsNOK 4.41m0.028%
NOK 110.5k
Audun Tornes
Chief Technology Officer4.1yrsNOK 2.92mno data
Jens Egil Bjorheim
Chief Medical Officer8.8yrsNOK 4.29mno data
Oivind Foss
Head of Clinical Operations7.6yrsNOK 2.71mno data
Orla Mc Callion
Head of Regulatory Affairs & QA3.4yrsNOK 2.37mno data
Torill Trones
Head of Officeno datano datano data

7.6yrs

Average Tenure

Experienced Management: ZLNA's management team is seasoned and experienced (7.6 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/28 23:22
End of Day Share Price 2025/03/28 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ultimovacs ASA is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Geir HolomDNB Markets